hVIVO (LON:HVO) Stock Price Passes Above 50 Day Moving Average – Here’s Why

hVIVO plc (LON:HVO)’s share price passed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of GBX 7.56 and traded as high as GBX 8.30. hVIVO shares last traded at GBX 7.88, with a volume of 2,097,438 shares traded.

Analysts Set New Price Targets

HVO has been the subject of several research analyst reports. Stifel Nicolaus restated a “hold” rating and set a GBX 10 price target on shares of hVIVO in a research report on Thursday, May 7th. Shore Capital Group restated a “buy” rating on shares of hVIVO in a research report on Wednesday, April 22nd. Two research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of GBX 15.

hVIVO Price Performance

The company has a debt-to-equity ratio of 38.75, a current ratio of 1.63 and a quick ratio of 1.16. The stock has a 50-day moving average price of GBX 7.56 and a 200 day moving average price of GBX 6.97. The firm has a market cap of £54.21 million, a price-to-earnings ratio of -9.05 and a beta of 1.69.

hVIVO (LON:HVO) last issued its quarterly earnings results on Wednesday, April 15th. The company reported GBX (0.87) earnings per share (EPS) for the quarter. The firm had revenue of GBX 4,677 million for the quarter. hVIVO had a negative return on equity of 14.65% and a negative net margin of 12.48%. As a group, equities research analysts forecast that hVIVO plc will post 1.5492958 earnings per share for the current fiscal year.

Insider Transactions at hVIVO

In other hVIVO news, insider Brendan Buckley sold 2,017,000 shares of the business’s stock in a transaction on Friday, April 24th. The stock was sold at an average price of GBX 9, for a total value of £181,530. Company insiders own 5.24% of the company’s stock.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.